Skip to main content

Table 1 Summary of demographic data between control and aromatherapy arm

From: Aromatherapy for the treatment of PONV in children: a pilot RCT

 

Control

Aromatherapy

Age (YEAR)

8.5 (95 % CI ±3.4)

6.9 (95 % CI ±3.1)

Sex (%male)

9/18 (50 %)

12/21 (57.1 %)

ASA (I or II)

100 %

100 %

Surgery

 ENT

8/18 44 %

17/21 81 %

 Ophthalmology

5/18 27.8 %

1/21 4.8 %

 Plastic surgery

2/18 11.1 %

0/21 0 %

 Orthopaedics

0/18 0 %

0/21 0 %

 Dental

1/18 5.6 %

3/21 14.3 %

 Urology

0/18 0 %

0/21 0 %

 General surgery

2/18 11.1 %

0/21 0 %

 OR time (minutes)

66 (95 % CI ±18)

64 (95 % CI ±34)

PONV Prophylaxis

 TIVA

4/18 22 %

4/21 19 %

 Ondansetron

14/18 77.8 %

15/21 71 %

 Dexamethasone

17/18 94.4 %

18/21 85.7 %

Pain management

 Acetaminophen

17/18 94.4 %

20/21 95.2 %

 Ketorolac

6/18 33 %

2/21 9.5 %

 Morphine dose (mg/kg)

0.14 (95 % CI ±0.1)

0.13 (95 % CI ±0.09)

  1. Continuous data were expressed as mean and 95 % CI. Otherwise data expressed as percentage of subjects meeting outcome